文献速递糖尿病

SLC2A2基因变异影响新诊断2型糖尿病患者的二甲双胍血糖反应

A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes.
PubMed 文献 · Diabetologia · 2018-11-09

本研究基于德国糖尿病研究前瞻性队列508例新诊断2型糖尿病患者,探讨SLC2A2基因rs8192675变异对二甲双胍血糖反应的影响。结果显示,在二甲双胍单药治疗组中,携带C等位基因的患者第一年空腹血糖下降幅度大于TT基因型患者(6.3 mmol/l vs 3.9 mmol/l,基因型差异2.4 mmol/l,p=0.02),基因型与治疗交互作用p<0.01。

要点

  • SLC2A2 rs8192675 C等位基因与二甲双胍单药治疗第一年空腹血糖下降更显著相关。
  • 仅二甲双胍单药组中C等位基因者血糖降幅大于TT型(6.3 vs 3.9 mmol/l,p=0.02)。
  • 基因型与治疗交互作用显著(p<0.01),提示该变异可修饰二甲双胍疗效。

核心结论

  • SLC2A2基因rs8192675 C等位基因与二甲双胍单药治疗第一年血糖反应改善相关。

研究设计与样本

  • 前瞻性德国糖尿病研究队列,纳入508例新诊断2型糖尿病患者(平均年龄53±10岁,65%男性,BMI 32±6 kg/m2,二甲双胍使用率57%)。
  • 采用高胰岛素-正葡萄糖钳夹和IVGTT进行代谢特征评估,使用双因素ANCOVA分析基因×治疗交互作用,校正年龄、性别、BMI和糖尿病病程。

主要发现

  • rs8192675 C等位基因与诊断时糖尿病症状患病率较高相关。
  • 二甲双胍单药组中,C等位基因患者第一年调整后血糖下降幅度大于TT基因型(6.3 mmol/l vs 3.9 mmol/l;基因型差异2.4 mmol/l,p=0.02;基因型交互作用p<0.01)。
  • 进一步校正诊断时血糖值后,二甲双胍单药组C等位基因与TT基因型间空腹血糖下降差异仍存在(基因型差异1.0 mmol/l,p=0.01;基因型×治疗交互作用p=0.06)。

关键数值与推荐

  • 二甲双胍单药治疗组:C等位基因者空腹血糖下降6.3 mmol/l,TT基因型者下降3.9 mmol/l,基因型差异2.4 mmol/l(p=0.02)。
  • 基因型与治疗交互作用(二甲双胍单药 vs 非药物治疗)p<0.01。
  • 校正诊断时血糖后基因型差异1.0 mmol/l(p=0.01),交互作用p=0.06。

临床怎么用

  • 对于新诊断2型糖尿病患者,SLC2A2 rs8192675基因型可能有助于预测二甲双胍单药治疗的血糖反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to investigate the modifying effect of the glucose transporter (GLUT2) gene SLC2A2 (rs8192675) variant on the glycaemic response to metformin in individuals recently diagnosed with type 2 diabetes. METHODS: Individuals with type 2 diabetes (n = 508) from the prospective German Diabetes Study (age [mean ± SD] 53 ± 10 years; 65% male; BMI 32 ± 6 kg/m2, metformin use 57%) underwent detailed metabolic characterisation (hyperinsulinaemic-euglycaemic clamp, IVGTT) during the first year after diagnosis. Participants provided self-reported data from the time of diagnosis. The change in fasting glucose was assessed in relation to SLC2A2 genotype and glucose-lowering treatment using two-way ANCOVA with gene×treatment interactions adjusted for age, sex, BMI and diabetes duration. RESULTS: The C variant allele of rs8192675 was associated with a higher prevalence of diabetes symptoms at diabetes diagnosis. In the metformin monotherapy group only, patients with a C allele showed a larger adjusted blood glucose reduction during the first year after diabetes diagnosis than patients with the TT genotype (6.3 mmol/l vs 3.9 mmol/l; genotype difference 2.4 mmol/l, p = 0.02; p value for genotype interaction [metformin monotherapy vs non-pharmacological therapy] <0.01). The greater decline in fasting glucose (CC/CT vs TT) in metformin monotherapy persisted after further adjusting for glucose values at diagnosis (genotype difference 1.0 mmol/l, p = 0.01; genotype×treatment interaction p = 0.06). CONCLUSIONS/INTERPRETATION: The variant rs8192675 in the SLC2A2 gene (C allele) is associated with an improved glucose response to metformin monotherapy during the first year after diagnosis in type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT01055093.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Rathmann W, Strassburger K, Bongaerts B, et al. A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes. Diabetologia. 2018. PMID: 30413829. doi:10.1007/s00125-018-4759-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。